Condition: Locally Advanced or Metastatic Solid Tumors · Sponsor: Dong-A ST Co., Ltd.
This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.
This description comes directly from the study's public registry record.
Jayun Jang · +82-2-920-8306 · janycan@donga.co.kr
Hye-yeong Han · hyhan@donga.co.kr
Always discuss trial participation with your own doctor first.
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06293651